AUS
NZ
UK
CA
USA
IND
Highlights:
-
AstraZeneca has acquired a license for a novel cholesterol-lowering drug, YS2302018, from CSPC Pharmaceutical for an initial payment of $100 million.
-
The drug targets the formation of lipoproteins linked to coronary artery disease and stroke, with significant potential for addressing cardiovascular disease.
-
AstraZeneca may pay up to an additional $1.92 billion based on development milestones and will receive tiered royalty payments upon sales.
AstraZeneca PLC {LSE:AZN} shares experienced a modest increase following the announcement of an exclusive license acquisition for a promising cholesterol-lowering drug, YS2302018. The UK's largest pharmaceutical company has agreed to pay $100 million initially to secure rights to this pre-clinical molecule, which has demonstrated potential in preventing the formation of lipoproteins—particles responsible for transporting cholesterol in the bloodstream.
The innovative molecule was discovered by Chinese company CSPC Pharmaceutical, which has indicated that YS2302018 effectively inhibits the formation of a specific type of lipoprotein associated with serious health risks such as coronary artery disease and stroke. AstraZeneca's strategy involves advancing this molecule into a commercially viable drug, with the potential for further payments of up to $1.92 billion contingent on the drug's successful development and commercialization milestones. Additionally, tiered royalty payments will be implemented once sales commence.
Sharon Barr, the head of biopharmaceuticals R&D at AstraZeneca, emphasized the significance of this acquisition in bolstering the company's cardiovascular pipeline. The drug is expected to aid patients in managing dyslipidaemia and related cardiometabolic conditions more effectively. With cardiovascular disease representing a leading cause of death globally, the development of novel therapies that address known risk factors is of paramount importance and aligns closely with AstraZeneca's strategic objectives.
The acquisition enhances AstraZeneca's cardiovascular portfolio, which has already contributed £3.2 billion in sales during the second quarter of 2024, accounting for 22% of the group's total revenue growth in the first half of the year. As AstraZeneca continues to expand its offerings in the cardiovascular, renal, and metabolism (CVRM) sectors, the addition of YS2302018 positions the company favorably in a market with significant unmet medical needs.
